AmBisome

DRUG16 trials

Conditions

BioequivalenceCandidemiaCandidiasisEffects of ImmunotherapyFungus DiseasesHIV/AIDS-associated TalaromycosisInfectionInvasive Aspergillosis

Phase 1

SCH708980 With and Without AmBisome for Visceral Leishmaniasis

WithdrawnNCT01437020

National Institute of Allergy and Infectious Diseases (NIAID)Effects of Immunotherapy, Leishmaniasis

Updated: 2013-08-28

An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects

CompletedNCT01652859

Taiwan Liposome CompanyNormal Healthy Subjects

Start: 2012-02-29End: 2012-12-31Updated: 2013-11-27

Pharmacokinetics and Safety of AmBisome and DKF-5122

CompletedNCT05749380

Dongkook Pharmaceutical Co., Ltd.Invasive Fungal Infections, Neutropenic Fever

Start: 2020-09-07End: 2022-01-28Updated: 2023-03-01

Bioequivalence of Amphotericin B Liposome for Injection

CompletedNCT05913921

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Bioequivalence

Start: 2023-06-02End: 2023-09-01Updated: 2023-09-28

Phase 2

PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation

CompletedNCT00326157

Gilead SciencesFungus Diseases

Start: 2006-06-30End: 2009-11-30Updated: 2010-02-12

Short Course Regimens for Treatment of PKDL (Sudan)

NCT03399955

Drugs for Neglected DiseasesPKDL - Post-Kala-Azar Dermal Leishmanioid

Start: 2018-05-09End: 2022-05-01Target: 110Updated: 2020-01-18

Phase 3

Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment

CompletedNCT00158730

Gilead SciencesInvasive Aspergillosis, Other Fungal Infections

Start: 2003-04-30End: 2005-01-31Target: 800Updated: 2005-11-18

Phase 4

Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants

CompletedNCT00001107

National Institute of Allergy and Infectious Diseases (NIAID)Candidiasis

End: 2005-11-30Target: 500Updated: 2010-08-27

Ambisome in Liver Transplant Patients

TerminatedNCT00161356

The University of Texas Health Science Center, HoustonLiver Transplantation

Start: 2005-09-30End: 2007-12-31Updated: 2008-06-23

COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis

CompletedNCT00334412

Gilead SciencesInvasive Aspergillosis

Start: 2004-03-31End: 2006-05-31Target: 30Updated: 2015-07-09

PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia

CompletedNCT00362544

Gilead SciencesLeukemia

Start: 2003-10-31End: 2006-03-31Target: 30Updated: 2015-07-09

CRITIC - Treatment of Candidemia and Invasive Candidiasis

CompletedNCT00670657

Gilead SciencesCandidemia, Invasive Candidiasis

Start: 2007-05-31End: 2009-01-31Target: 39Updated: 2009-03-27

Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis

NCT01566552

Banaras Hindu UniversityVisceral Leishmaniasis

Start: 2014-06-30End: 2017-12-31Target: 1300Updated: 2014-01-22

Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh

CompletedNCT03311607

Medecins Sans Frontieres, NetherlandsPost-kala-azar Dermal Leishmaniasis

Start: 2014-04-08End: 2015-10-14Updated: 2017-10-17

Unknown Phase

Antimicrobial PK in Infants With Suspected or Confirmed Infection

CompletedNCT00491426

Duke UniversityInfection

Start: 2006-01-31End: 2010-11-30Updated: 2012-11-19

Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis

Not yet recruitingNCT06926569

Shanghai Public Health Clinical CenterHIV/AIDS-associated Talaromycosis

Start: 2025-05-01End: 2026-05-01Target: 116Updated: 2025-04-13

Related Papers

Pharmacokinetic Equivalence of Amphosom<sup>TM</sup>, a Newly Developed Liposomal Amphotericin B, to Ambisome<sup>Ⓡ</sup>.

2026-01-08

Single high-dose liposomal amphotericin B plus B/F/TAF for AIDS-associated talaromycosis in China: a multicentre randomised controlled trial protocol.

2025-11-19

Differences in the Cellular Immune Response during and after Treatment of Sudanese Patients with Post-kala-azar Dermal Leishmaniasis, and Possible Implications for Outcome.

2024-07-152 citations

Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study

PLoS neglected tropical diseases2023-11-2130 citations